OverviewSuggest Edit

22nd Century Group is a plant biotechnology company developing tobacco harm reduction and smoking cessation products. Its technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.

TypePublic
Founded1998
HQWilliamsville, US
Websitexxiicentury.com

Latest Updates

Employees (est.) (Feb 2020)67(-18%)
Revenue (FY, 2019)$25.8 M(-2%)
Share Price (Sept 2020)$0.6 (-1%)
Cybersecurity ratingAMore

Key People/Management at 22nd Century Group

Michael Zercher

Michael Zercher

President & Chief Operating Officer
James A. Mish

James A. Mish

Chief Executive Officer
Juan Sanchez Tamburrino

Juan Sanchez Tamburrino

Vice President of Research and Development
John Franzino

John Franzino

Chief Financial Officer
John T. Brodfuehrer

John T. Brodfuehrer

Vice President of Strategy
John D. Pritchard

John D. Pritchard

Vice President of Regulatory Science
Show more

22nd Century Group Office Locations

22nd Century Group has an office in Williamsville
Williamsville, US (HQ)
8560 Main St #4
Show all (1)

22nd Century Group Financials and Metrics

22nd Century Group Revenue

Embed Graph
View revenue for all periods
22nd Century Group's revenue was reported to be $25.83 m in FY, 2019 which is a 2.2% decrease from the previous period.
USD

Revenue (Q2, 2020)

6.4m

Net income (Q2, 2020)

(5.1m)

EBIT (Q2, 2020)

(4.8m)

Market capitalization (16-Sept-2020)

82.0m

Closing stock price (16-Sept-2020)

0.6

Cash (30-Jun-2020)

844.0k

EV

85.0m
22nd Century Group's current market capitalization is $82 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

12.3m16.6m26.4m25.8m

Revenue growth, %

44%35%59%(2%)

Cost of goods sold

12.7m17.3m25.5m25.8m

Gross profit

(429.7k)(707.9k)899.0k14.5k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.2m3.9m4.5m6.1m6.9m6.3m6.3m5.8m6.5m7.1m6.4m

Cost of goods sold

2.5m4.1m4.9m6.0m6.8m6.1m6.4m5.9m6.5m6.8m

Gross profit

(273.9k)(165.1k)(340.4k)71.6k161.7k150.9k(102.9k)(86.3k)(21.1k)287.0k

Gross profit Margin, %

(12%)(4%)(8%)1%2%2%(2%)(1%)0%4%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.5m3.7m604.9k485.1k

Accounts Receivable

41.0k957.1k871.3k866.9k

Prepaid Expenses

195.6k746.8k928.4k648.1k

Inventories

3.1m3.3m3.0m2.3m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.6m)(13.0m)(8.0m)(26.6m)

Depreciation and Amortization

744.2k849.0k1.2m1.2m

Inventories

(531.4k)(129.2k)333.6k(207.6k)

Accounts Payable

(136.3k)473.8k323.1k(732.1k)
USDFY, 2016

Revenue/Employee

267.0k

Financial Leverage

1.1 x
Show all financial metrics

22nd Century Group Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Manufacturing Facilities

1 1 1 1

Research Cigarettes Produced to Date

22 m24 m28 m28 m
Show all operating metrics

22nd Century Group Acquisitions / Subsidiaries

Company NameDateDeal Size
22nd Century Limited, LLC
Botanical Genetics, LLC
Goodrich Tobacco Company, LLC
Heracles Pharmaceuticals, LLC
NASCO Products, LLC

22nd Century Group Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

22nd Century Group Online and Social Media Presence

Embed Graph

22nd Century Group News and Updates

22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer

Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including cannabinoids, and related consumer products

22nd Century Group Appoints New Director and New Chairman

Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new me…

FDA authorizes low-nicotine cigarettes by 22nd Century Group for public sale

The FDA cleared applications from 22nd Century Group to sell its Moonlight and Moonlight Menthol cigarettes, which contain less nicotine than conventional cigarettes.

22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and l…

22nd Century Group Comments on Delay of Reduced Nicotine Rule for Cigarettes

Modified Risk Tobacco Product application for Very Low Nicotine Content cigarettes becoming increasingly important to people who smoke Modified Risk Tobacco Product application for Very Low Nicotine Content cigarettes becoming increasingly important to people who smoke

Thinking about buying stock in Atossa Genetics, Cronos Group, New Age Beverages Co, Tesaro Inc. or 22nd Century Group Inc.?

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATOS, CRON, NBEV, TSRO, and XXII. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

22nd Century Group Blogs

22nd Century’s New Study Confirms Very Low Nicotine Content Cigarettes Result in 97% Less Nicotine in Smoker’s Bloodstream

WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is focused on tobacco harm reduction and hemp/cannabis research, announced today the results of a recently completed, company-sponsored study involvin…

22nd Century Files 2018 Annual Report and Announces Conference Call to Provide Business Update

The FDA has accepted for review the Company’s MRTPA for VLNTM cigarettes WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine C…

22nd Century Files Modified Risk Tobacco Product (MRTP) Application with the FDA for the Company’s Very Low Nicotine Content Cigarettes

VLNTM cigarettes contain at least 95% less nicotine than each of the 100 leading cigarette brands in the United States. WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on toba…

22nd Century’s Low-THC Cannabis sativa L. Research Activities Receive Legislative Boost

President Trump Signs Bill Legalizing Low-THC Cannabis WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that the …

22nd Century Files Premarket Tobacco Application (PMTA) with the FDA

A PMTA is an important first step toward achieving potentially the first – and only – Modified Risk Tobacco Product marketing order for a combustible cigarette WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American:XXII), a plan…

22nd Century Files 2018 Third Quarter Report

Company posts $6.3 million net income for third quarter; substantial MRTP application investments will result in fourth quarter submission to the FDA WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)-- 22nd Century Group, Inc. (NYSE American:XXII), a plant biotechn…
Show more

22nd Century Group Frequently Asked Questions

  • When was 22nd Century Group founded?

    22nd Century Group was founded in 1998.

  • Who are 22nd Century Group key executives?

    22nd Century Group's key executives are Michael Zercher, James A. Mish and Juan Sanchez Tamburrino.

  • How many employees does 22nd Century Group have?

    22nd Century Group has 67 employees.

  • What is 22nd Century Group revenue?

    Latest 22nd Century Group annual revenue is $25.8 m.

  • What is 22nd Century Group revenue per employee?

    Latest 22nd Century Group revenue per employee is $385.6 k.

  • Who are 22nd Century Group competitors?

    Competitors of 22nd Century Group include GCANRx, CLS Holdings USA and Kentucky BioProcessing.

  • Where is 22nd Century Group headquarters?

    22nd Century Group headquarters is located at 8560 Main St #4, Williamsville.

  • Where are 22nd Century Group offices?

    22nd Century Group has an office in Williamsville.

  • How many offices does 22nd Century Group have?

    22nd Century Group has 1 office.